Obstetrics & Gynecology

News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Discovery Could Lead to Drug Therapy for Hypopigmentation Conditions

three petri dishes with skin cells above microscopic images of the cells

An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders.

Such disorders, which include severe genetic forms of oculocutaneous albinism (OCA) as well as inflammation-caused hypopigmented skin patches, are characterized by abnormally low or even zero levels of melanin in cells. The lack of this ultraviolet-absorbing and antioxidant pigment can result in increased skin cancer risk, vision impairments due to improper retinal development, and social difficulties.

headshot of a man

Dr. Jonathan Zippin

Cancer Evolution Study Reveals Biology of Glioma Progression

illustration of a brain tumor in a man

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham. The findings showcase the power of modern laboratory technology for illuminating cancer development and could inform future treatments and prognostic measures for gliomas.

Dr. Dan Landau

Dr. Dan Landau. Credit: Roger Tully

BioVenture eLab Secures $1.5 Million State Grant to Broaden Weill Cornell Entrepreneurial Ecosystem

A man wearing business attire is speaking at a podium in front of an audience.

Weill Cornell Medicine has received a four-year, $1.5 million grant from New York’s Empire State Development to increase resources available through BioVenture eLab, the institution’s hub for biomedical entrepreneurship. The grant is among the first the state has awarded through its New York Global Entrepreneurs Program, which was established last year to attract innovative life sciences entrepreneurs to launch or expand their businesses in New York.

BioVenture eLab aims to generate entrepreneurship and commercialization opportunities from within the academic medical institution’s community with the state funding. It will also enable BioVenture eLab to recruit international founders in-house to help kindle enterprise expertise among Weill Cornell Medicine faculty and trainees.

“The grant allows us to combine resources from New York state as well as resources from Weill Cornell and the greater Cornell ecosystems to bring inventions that can impact patients to market,” said BioVenture eLab Director Loren Busby.

Contact Us